Ventyx Biosciences, Inc.
VTYX
$1.20
-$0.06-4.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.76% | -3.39% | -7.90% | 12.73% | -0.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.61% | -33.47% | -37.51% | -1.84% | 30.53% |
| Operating Income | 35.61% | 33.47% | 37.51% | 1.84% | -30.53% |
| Income Before Tax | 37.22% | 34.76% | 40.00% | 0.92% | -32.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.22% | 34.76% | 40.00% | 0.92% | -32.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.22% | 34.76% | 40.00% | 0.92% | -32.77% |
| EBIT | 35.61% | 33.47% | 37.51% | 1.84% | -30.53% |
| EBITDA | 35.66% | 33.55% | 37.58% | 1.94% | -30.53% |
| EPS Basic | 47.62% | 45.64% | 50.21% | 7.64% | -27.48% |
| Normalized Basic EPS | 47.61% | 45.63% | 50.21% | 7.63% | -27.47% |
| EPS Diluted | 47.62% | 45.64% | 50.21% | 7.64% | -27.48% |
| Normalized Diluted EPS | 47.61% | 45.63% | 50.21% | 7.63% | -27.47% |
| Average Basic Shares Outstanding | 19.86% | 20.02% | 20.49% | 7.27% | 4.15% |
| Average Diluted Shares Outstanding | 19.86% | 20.02% | 20.49% | 7.27% | 4.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |